Michael Shnaidman

455 total citations
13 papers, 314 citations indexed

About

Michael Shnaidman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Michael Shnaidman has authored 13 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Michael Shnaidman's work include Cancer Immunotherapy and Biomarkers (5 papers), Renal cell carcinoma treatment (4 papers) and Economic and Financial Impacts of Cancer (2 papers). Michael Shnaidman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (5 papers), Renal cell carcinoma treatment (4 papers) and Economic and Financial Impacts of Cancer (2 papers). Michael Shnaidman collaborates with scholars based in United States, United Kingdom and Japan. Michael Shnaidman's co-authors include Andrew Gelman, Ginger L. Chew, Zhiliang Ying, Heikki Koskinen, Eero Pukkala, Kari Hemminki, Antti Karjalainen, Yongliang Li, Harri Vainio and Paul W. Brandt‐Rauf and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Clinical Cancer Research.

In The Last Decade

Michael Shnaidman

13 papers receiving 310 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Shnaidman United States	9	153	102	87	55	48	13	314
Paul Rhyne United States	11	146 1.0×	197 1.9×	144 1.7×	38 0.7×	14 0.3×	19	441
Nicolas Frances Switzerland	11	221 1.4×	191 1.9×	33 0.4×	63 1.1×	53 1.1×	22	436
Masturah Bte Mohd Abdul Rashid Singapore	9	166 1.1×	105 1.0×	33 0.4×	18 0.3×	24 0.5×	19	371
Jennifer Rauw Canada	8	232 1.5×	123 1.2×	48 0.6×	12 0.2×	39 0.8×	14	398
Itziar Irurzun‐Arana Spain	10	210 1.4×	173 1.7×	46 0.5×	16 0.3×	59 1.2×	17	364
A Eggermont Netherlands	6	173 1.1×	216 2.1×	178 2.0×	29 0.5×	47 1.0×	9	377
Ashim Subedee United States	4	124 0.8×	96 0.9×	34 0.4×	12 0.2×	44 0.9×	6	332
J.E. Carey United Kingdom	8	151 1.0×	56 0.5×	193 2.2×	95 1.7×	41 0.9×	10	461
Imran Chaudhary United States	8	140 0.9×	216 2.1×	21 0.2×	14 0.3×	40 0.8×	29	391
Rene Quevedo Canada	9	249 1.6×	182 1.8×	85 1.0×	12 0.2×	45 0.9×	15	503

Countries citing papers authored by Michael Shnaidman

Since Specialization

Citations

This map shows the geographic impact of Michael Shnaidman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Shnaidman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Shnaidman more than expected).

Fields of papers citing papers by Michael Shnaidman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Shnaidman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Shnaidman. The network helps show where Michael Shnaidman may publish in the future.

Co-authorship network of co-authors of Michael Shnaidman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Shnaidman. A scholar is included among the top collaborators of Michael Shnaidman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Shnaidman. Michael Shnaidman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Hong, David S., Shadia I. Jalal, Elena Elimova, et al.. (2022). SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.. Journal of Clinical Oncology. 40(4_suppl). TPS363–TPS363. 7 indexed citations

Choueiri, Toni K., Brian I. Rini, James Larkin, et al.. (2017). Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. Journal of Clinical Oncology. 35(15_suppl). TPS4594–TPS4594. 16 indexed citations

Motzer, Robert J., Toni K. Choueiri, James Larkin, et al.. (2016). Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC). Annals of Oncology. 27. vi293–vi293. 5 indexed citations

Powles, Thomas, Petros Grivas, Jeanny B. Aragon‐Ching, et al.. (2016). A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). Annals of Oncology. 27. vi292–vi292. 14 indexed citations

Larkin, James, Michael S. Gordon, Fiona Thistlethwaite, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.. Journal of Clinical Oncology. 34(15_suppl). TPS4580–TPS4580. 11 indexed citations

Liu, Mengling, et al.. (2016). Design and analysis of clinical trials in the presence of delayed treatment effect. Statistics in Medicine. 35(11). 1774–1779. 9 indexed citations

Colombo, Nicoletta, Mary L. Disis, Keiichi Fujiwara, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) ± pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer: The phase III JAVELIN Ovarian 200 trial.. Journal of Clinical Oncology. 34(15_suppl). TPS5600–TPS5600. 6 indexed citations

Ledermann, Jonathan A., Kei Fujiwara, I. Vergote, et al.. (2016). PHASE 3 TRIAL OF AVELUMAB (ANTI-PD-L1) IN COMBINATION WITH AND/OR FOLLOWING PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH UNTREATED OVARIAN CANCER. 1 indexed citations

Dang, Nam H., Michinori Ogura, Sylvie Castaigné, et al.. (2014). Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. Journal of Clinical Oncology. 32(15_suppl). 8529–8529. 14 indexed citations

10.

Rajan, Arun, Ronan J. Kelly, Jane B. Trepel, et al.. (2011). A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas. Clinical Cancer Research. 17(21). 6831–6839. 107 indexed citations

11.

Buchman, Alan L., Seymour Katz, Michael Shnaidman, & David R. Jacobs. (2006). Effect of Teduglutide on Patients With Moderate-Severe Crohn’s Disease After 8 Weeks of Therapy: A Prospective, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 131(3). 949–950. 8 indexed citations

12.

Gelman, Andrew, Ginger L. Chew, & Michael Shnaidman. (2004). Bayesian Analysis of Serial Dilution Assays. Biometrics. 60(2). 407–417. 42 indexed citations

13.

Li, Yongliang, Antti Karjalainen, Heikki Koskinen, et al.. (2004). p53 autoantibodies predict subsequent development of cancer. International Journal of Cancer. 114(1). 157–160. 74 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact